AF4p12, a human homologue to the furry gene of Drosophila, as a novel MLL fusion partner

Cancer Research

Volumn 65, Issue 15, 2005, Pages 6521-6525

  Hayette, Sandrine ^a   Cornillet Lefebvre, Pascale ^c   Tigaud, Isabelle ^a   Struski, Stéphanie ^c   Forissier, Stéphanie ^b   Berchet, Adrien ^b   Doll, Diane ^b   Gillot, Lucile ^c   Brahim, Wajih ^d   Delabesse, Eric ^d   Magaud, Jean Pierre ^a   Rimokh, Ruth ^b,e  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c SERVICE DE DERMATOLOGIE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE ZIPPER PROTEIN;

AF4P12 GENE; AGED; ARTICLE; CASE REPORT; CHROMOSOME 11; CHROMOSOME TRANSLOCATION; DNA BINDING; FEMALE; FLT3 GENE; FURRY GENE; FUSION GENE; GENE; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HOXA9 GENE; HUMAN; LEUKEMIA; MLL GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSCRIPTION INITIATION;

AGED; AMINO ACID SEQUENCE; ANIMALS; ARTIFICIAL GENE FUSION; BASE SEQUENCE; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 4; DNA-BINDING PROTEINS; DROSOPHILA; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MOLECULAR SEQUENCE DATA; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASMS, SECOND PRIMARY; ONCOGENE PROTEINS, FUSION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENES; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 23044479837     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1325     Document Type: Article

References (18)

1. Huret JL, Dessen P, Bernheim A. An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners. Leukemia 2001;15:987-9.
2. Hayette S, Tigaud I, Maguer-Satta V, et al. Recurrent involvement of the MLL gene in adult T-lineage acute lymphoblastic leukemia. Blood 2002;99:4647-9.
3. Daser A, Rabbitts TH. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev 2004;18:965-74.
4. DiMartino JF, Cleary ML. Mll rearrangements in haematological malignancies: lessons from clinical and biological studies. Br J Haematol 1999;106:614-26.
5. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001;20:5695-707.
6. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002;30: 41-7.
7. Ferrando AA, Armstrong SA, Neuberg DS, et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003;102:262-8.
8. Megonigal MD, Rappaport EF, Jones DH, et al. Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias. Proc Natl Acad Sci U S A 1997;94:11583-8.
9. Cong J, Geng W, He B, Liu J, Charlton J, Adler PN. The furry gene of Drosophila is important for maintaining the integrity of cellular extensions during morphogenesis. Development 2001;128: 2793-802.
10. Emoto K, He Y, Ye B, et al. Control of dendritic branching and tiling by the Tricornered-kinase/Furry signaling pathway in Drosophila sensory neurons. Cell 2004;119:245-56.
11. Hirata D, Kishimoto N, Suda M, et al. Fission yeast Mor2/Cps12, a protein similar to Drosophila Furry, is essential for cell morphogenesis and its mutation induces Weel-dependent G(2) delay. EMBO J 2002;21: 4863-74.
12. He Y, Fang X, Emoto K, Jan YN, Adler PN. The tricornered Ser/Thr protein kinase is regulated by phosphorylation and interacts with furry during Drosophila wing hair development. Mol Biol Cell 2005;16:689-700.
13. Tamaskovic R, Bichsel SJ, Hemmings BA. NDR family of AGC kinases-essential regulators of the cell cycle and morphogenesis. FEBS Lett 2003;546:73-80.
14. DiMartino JF, Ayton PM, Chen EH, Naftzger CC, Young BD, Cleary ML. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood 2002;99:3780-5.
15. Slany RK, Lavnu C, Cleary ML. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol 1998;18:122-9.
16. DiMartino JF, Miller T, Ayton PM, et al. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood 2000;96:3887-93.
17. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42.
18. Tsutsumi S, Taketani T, Nishimura K, et al. Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements. Cancer Res 2003;63:4882-7.